U.S. government to study allergic reactions to COVID-19 vaccines

U.S. government to study allergic reactions to COVID-19 vaccines
Jaimy Lee
·1 min read

The National Institutes of Health said Wednesday that it started a [l:clinical study|https://clinicaltrials.gov/ct2/show/NCT04761822|NEW] assessing allergic reactions to the mRNA COVID-19 vaccines developed by Moderna Inc. and BioNTech SE /Pfizer Inc. . The aim is to understand who is at increased risk, including people with a history of allergic reactions or those who have been diagnosed with a mast cell disorder. (Mast cells are part of the body's immune system. When those cells mutate, it can cause one of several rare disorders.) The Phase 2 clinical trial, which is being funded by the National Institute of Allergy and Infectious Diseases, will enroll 3,400 adults who fit one of three categories: people who have previously reported a severe allergic reaction to food, insects, or a medication; people who have been diagnosed with a mast cell disorder; or individuals without a history of either. The Centers for Disease Control and Prevention [l:says|https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html|NEW] that anaphylaxis as a result of a COVID-19 vaccine occurs in up to 5 people out of every 1 million who have been vaccinated. These events "almost always" occur within 30 minutes of receiving the shot.